恩度联合TACE并持续恩度静脉滴注治疗原发性肝癌临床观察(2)
 |
| 第1页 |
参见附件。
参考文献：
[1]MOLINAR I M , KACHURA J R , DIXON E, et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre [J]. Clin Oncol(RColl Radiol),2006,18(9):684 -692.
[2]Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma[J]. Cancer Lett, 2006,240: 157-69.
[3]王金万,孙燕.重组人血管内皮抑制素III期临床研究[J].中国医疗前言,2006,3:87-90.
[4]黄莹,邓钢,郭金和,等.动脉内恩度联合化疗栓塞术治疗原发性肝癌前后CT灌注成像的随机对照研究[J].临床放射学杂志,2009,28(1):96-100.
[5] Pepper MS. Manipulating angiogenesis from basic science to the bed side[J]. Arterioscler Thromb VascBiol,1997,17:605-19.
[6]Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies[J]. J Clin Oncol,2002,20:3906-27.
[7]Gasparini G, Longo R, Fanelli M, et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions[J]. J Clin Oncol, 2005,23:1295-311.
[8]Ling Y, Yang Y, Lu N, et al.Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biophys Rec Commun[J],2007,361:79-84.
編辑/孙杰
您现在查看是摘要介绍页，详见PDF附件。